freeze-dried powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
=== 2023: French Open semifinals, Hamburg title === Zverev returned to the tour for the first time since his ankle injury by participating at the inaugural United Cup where he lost in straight sets to Jiří Lehečka and Taylor Fritz. Seeded 12th at the Australian Open, he won his first match since June 2022 by beating lucky loser, Juan Pablo Varillas, in the first round in five sets. He was defeated in the second round by American and lucky loser, Michael Mmoh, in four sets. After the Australian Open, Zverev represented Germany in the Davis Cup tie against Switzerland. He won his first match over Stan Wawrinka. He lost his second match to Marc-Andrea Hüsler. Switzerland ended up winning the tie over Germany 3–2. Seeded eighth at the Rotterdam Open, he was eliminated from the tournament in the second round by Dutch wildcard, Tallon Griekspoor, in three sets. Seeded fourth at the Qatar ExxonMobil Open, he fell in the second round to wildcard, former world No. 1, two-time champion, and eventual finalist, Andy Murray. In March, he played at the Dubai Championships. Seeded seventh, he reached the semifinals where he lost to second seed, defending champion, and eventual finalist, Andrey Rublev. Zverev began his early U.S. hard court campaign at the Indian Wells Masters. Seeded 12th, he reached the fourth round but lost to fifth seed, world No. 6, and eventual finalist, Daniil Medvedev, in three close sets. Seeded 13th at the Miami Open, he was beaten in the second round by wildcard Taro Daniel. Zverev began his clay-court season at the Monte-Carlo Masters.
Genetic testing for Huntington's disease has raised several ethical issues, which include defining how mature an individual should be before being considered eligible for testing, ensuring the confidentiality of results, and deciding whether companies should be allowed to use test results for decisions on employment, life insurance or other financial matters. There was controversy when Charles Davenport proposed in 1910 that compulsory sterilization and immigration control be used for people with certain diseases, including HD, as part of the eugenics movement. In vitro fertilization has some issues regarding its use of embryos. Some HD research has ethical issues due to its use of animal testing and embryonic stem cells. The development of an accurate diagnostic test for HD has caused social, legal, and ethical concerns over access to and use of a person's results. Many guidelines and testing procedures have strict procedures for disclosure and confidentiality to allow individuals to decide when and how to receive their results and also to whom the results are made available. Insurance companies and businesses are faced with the question of whether to use genetic test results when assessing an individual, such as for life insurance or employment. The United Kingdom's insurance companies agreed with the Department of Health and Social Care that until 2017 customers would not need to disclose predictive genetics tests to them, but this agreement explicitly excluded the government-approved test for Huntington's when writing policies with a value over £500,000.
By the end of 2017, it was announced that Catherine Keener would star opposite Carrey in Kidding. The series lasted two seasons. Carrey was also the subject of two documentaries in 2017. The first, a short subject entitled I Needed Color about his lifelong passion for art, was released online in the summer. Later that year another documentary, Jim & Andy: The Great Beyond—Featuring a Very Special, Contractually Obligated Mention of Tony Clifton, premiered at The Venice Film Festival and was later picked up by Netflix. The film chronicles the behind-the-scenes drama during the shooting of Man on the Moon, when he never broke character as Andy Kaufman. It incorporates footage that was shot for the film's electronic press kit but ultimately pulled by Universal as they felt that it was too damaging.
Mecasermin rinfabate (INN, USAN) (brand name Iplex), also known as rhIGF-1/rhIGFBP-3, is a drug consisting of recombinant human insulin-like growth factor 1 (IGF-1) and recombinant human insulin-like growth factor binding protein-3 (IGFBP-3) which is used for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease). It is similar in action to mecasermin, but with fewer side effects (such as hypoglycemia).
Sources: en.wikipedia.org
=== Background === Early methods of secondary structure prediction, introduced in the 1960s and early 1970s, focused on identifying likely alpha helices and were based mainly on helix-coil transition models. Significantly more accurate predictions that included beta sheets were introduced in the 1970s and relied on statistical assessments based on probability parameters derived from known solved structures. These methods, applied to a single sequence, are typically at most about 60–65% accurate, and often underpredict beta sheets. Since the 1980s, artificial neural networks have been applied to the prediction of protein structures. The evolutionary conservation of secondary structures can be exploited by simultaneously assessing many homologous sequences in a multiple sequence alignment, by calculating the net secondary structure propensity of an aligned column of amino acids. In concert with larger databases of known protein structures and modern machine learning methods such as neural nets and support vector machines, these methods can achieve up to 80% overall accuracy in globular proteins. The theoretical upper limit of accuracy is around 90%, partly due to idiosyncrasies in DSSP assignment near the ends of secondary structures, where local conformations vary under native conditions but may be forced to assume a single conformation in crystals due to packing constraints.
Plane Poiseuille flow is flow created between two infinitely long parallel plates, separated by a distance h with a constant pressure gradient G = −dp/dx is applied in the direction of flow. The flow is essentially unidirectional because of infinite length. The Navier–Stokes equations reduce to
=== Red blood cell rejuvenation === Red blood cell rejuvenation is a method which aims to increase the levels of 2,3-diphosphoglycerate (2,3-DPG) and ATP in stored red blood cell concentrates, as the levels of both 2,3-DPG and ATP decrease over time. The rejuvenation process includes incubation of the red blood cells with a rejuvenation solution and subsequent washing. ATP is an important driver of a number of metabolic functions of the red blood cell, and declined ATP levels have been linked to reduced post-transfusion in vivo survival of the red blood cells. High levels of 2,3-DPG facilitates oxygen unloading from the red blood cells in the capillaries.
4-HO-MET, also known as 4-hydroxy-N-methyl-N-ethyltryptamine, as well as metocin or methylcybin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It is a close structural analogue of psilocin (4-HO-DMT) and is the 4-hydroxyl analogue of methylethyltryptamine (MET). 4-HO-MET was discovered by Alexander Shulgin in the 1970s. It was first described in the literature by David Repke and colleagues in 1981. The drug was encountered as a novel recreational and designer drug by 2008. It is openly sold as a legal recreational drug in the United States.
The Single Cell resource presents comprehensive data on gene expression across various human tissues and cell types, utilizing single cell RNA sequencing (scRNAseq), cell sorting, single nuclei RNA sequencing (snRNAseq), Deep Visual Proteomics (based on mass spectrometry), and bulk RNAseq correlation analyses. The resource provides insights into mRNA and protein expression patterns, gene specificity, and expression clustering with single cell types, immune cells and brain single nuclei. The Single Cell Resource includes five main datasets: - The Single cell type section, providing the expression profiles across 154 cell types from 34 human tissues, and cell type specificity based on gene expression. - The Deep Visual Proteomics section, providing protein detection in 27 cell types from 14 tissue types - The Tissue cell type section, providing the predicted cell-type expression specificity based on bulk RNAseq - The Single nuclei brain section, providing more details regarding cell type specificity within the brain, based on single nuclei RNAseq - The Immune cell section, providing expression comparison between sorted immune cells The Cancer resource is based on mRNA expression data from 21 cancer types as well as protein data from 20 cancers analyzed by IHC and 11 cancer types analyzed using MS. This data is displayed together with millions of in-house generated immunohistochemically stained tissue sections images and Kaplan-Meier plots showing the correlation between mRNA expression of each human protein gene and cancer patient survival.
Sources: en.wikipedia.org
=== Anion exchange resins === Strong base anion (SBA) resins: Type 1 SBA resins: Greatest affinity for the weak acids and commonly present during a water demineralization process. Type 3 SBA resins: Lower chemical stability than Type 1 but better regeneration efficiency. Weak base anion (WBA) resins: Act as acid absorbers; capable of sorbing strong acids with a high capacity and are readily regenerated with caustic.
Deon Frederick McNeilly. Chair, Newcastle Athletics Club, County Down. For services to Athletics in Northern Ireland. Robert Douglas McRae. Poppy Appeal Organiser (West), Poppyscotland. For services to Veterans. Harry Charles Lawrence Meade. For services to the community in Goathurst, Somerset. Christine Mellor. General Manager, Library Service, North Yorkshire Council. For services to Public Libraries. Robin John Mercer. Managing Director, Hillmount Garden Centre. For services to Business and to the Economy in Northern Ireland. Melvin James Metcalf. Head of Services, ARCH Sexual Violence Charity. For services to LGBT+ Victim-Survivors of Sexual Violence in the North East. Stephen Brian Michael. For services to the community in Kingsand, Cornwall. June Miller. For services to the community in Stanton, Suffolk. John Minhinick. Lately Chair, Fife Branch, Parkinson's UK. For services to People with Parkinson's Disease in Fife. Norman Alexander Mitchell. Chair of Trustees, Lockleaze Sports Centre. For services to Sport in Bristol. Brian Desmond Francis Mooney. Member, Common Council, City of London Corporation. For services to the community in the City of London and in Coggeshall, Essex. Jane Elizabeth Morris-Eyton. For services to the community in Bootle, Cumbria. Adrian David Morrow. Estate Manager, Glenarm Castle and Chief Executive, Irish Grouse Conservation Trust. For voluntary services to Habitat Conservation and to the community in County Antrim. Gloria Moss. Sussex President, British Red Cross. For voluntary service to the community in Sussex. Ellen Jane Muers.
In July 1991, BOR administered their first Computer adaptive tests the ASCP headquarters for the Medical Technologist (MT), Medical Laboratory Technician (MLT), Phlebotomy Technician (PBT), Cytotechnologist (CT), and Histologic Technician (HT) certification examinations. In 1994, BOR changed their examination format to Computerized adaptive testing (CAT). In 2004, the BOR implemented the Certification Maintenance Program (CMP) requiring continuing education every three years to remain certified.
Beta blockers are used to treat anxiety disorders including performance anxiety, panic disorder, generalized anxiety disorder, and specific phobias. They are not formally approved for anxiolytic use by the United States Food and Drug Administration. However, many clinical studies have found beta blockers to be effective for anxiety, though the exact mechanism of action is unclear. A 2025 systematic review and meta-analysis found widespread prescription of beta blockers, namely propranolol, for the treatment of anxiety disorders, but found no evidence of a beneficial effect relative to placebo or benzodiazepines in people with social phobia or panic disorder. However, the quality of evidence, including both numbers of studies and patients as well as quality and risk of bias of those studies, was limited. Findings were similar in a previous 2016 systematic review and meta-analysis. Beta blockers that have been used to treat anxiety include propranolol, atenolol, pindolol, nadolol, betaxolol, and oxprenolol. It is thought that beta blockers do not directly treat psychological symptoms of anxiety, but can help control physical symptoms such as palpitations, and this may interfere with a positive feedback loop to indirectly reduce psychological anxiety. Highly lipophilic beta blockers like propranolol, which are centrally permeable, and highly hydrophilic beta blockers like atenolol, which are peripherally selective, appear to have similar benefits on performance anxiety, suggesting that their anxiolytic effects are mediated peripherally.
=== Impaired wound healing === Individuals taking sirolimus are at increased risk of experiencing impaired or delayed wound healing, particularly if they have a body mass index more than 30 kg/m2 (classified as obese).
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.